2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2165

Natural Language Processing to Rapidly Identify Potential Signals for Adverse Events Using Electronic Medical Record Data: Example of Arthralgias and Vedolizumab
Abstract Number: 2848

Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
Abstract Number: 922

Negative Regulation of IL-17 Receptor Signaling By Regnase-1 Limits Immunopathology in a Mouse Model of Psoriatic Skin Disease
Abstract Number: 1047

Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
Abstract Number: 2265

NET-Inducing Capacity Is a Biomarker in ANCA-Associated Vasculitis Independent of ANCA Antibodies
Abstract Number: 589

Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Abstract Number: 1437

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Abstract Number: 1627

Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Abstract Number: 1348

Neuromyelitis Optica: Patient Characteristics and Treatment Patterns Among Rheumatologists Versus Non-Rheumatologists
Abstract Number: 3102

Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Abstract Number: 2853

Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity
Abstract Number: 233

New Cardiovascular Risk Factors Screening in Patients with Gout
Abstract Number: 872

New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study
Abstract Number: 1359

New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases
Abstract Number: 2763

New Treatment Option for SAPHO?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].